{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:25:26Z","timestamp":1793057126971,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.tmrv.2025.150935","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:40:47Z","timestamp":1763656847000},"page":"150935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Practical Review of Adaptive Platform Trials"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-5065","authenticated-orcid":false,"given":"Natalia Alejandra","family":"Angeloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill KJ","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lamontagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tmrv.2025.150935_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00134-021-06587-9","article-title":"Randomised clinical trials in critical care: past, present and future","volume":"48","author":"Granholm","year":"2022","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.tmrv.2025.150935_bib0002","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1164\/rccm.201401-0056CP","article-title":"Outcomes and statistical power in adult critical care randomized trials","volume":"189","author":"Harhay","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.tmrv.2025.150935_bib0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tmrv.2025.150935_bib0004","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.seminoncol.2015.07.009","article-title":"The master protocol concept","volume":"42","author":"Redman","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.tmrv.2025.150935_bib0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.tmrv.2025.150935_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3109","article-title":"Characteristics, progression, and output of randomized platform trials: a systematic review","volume":"7","author":"Griessbach","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.tmrv.2025.150935_bib0007","first-page":"S231","article-title":"An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: rationale and proposal","volume":"62","author":"Tolles","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2025.150935_bib0008","unstructured":"McQuilten Z. Protocol for \"Role of antibiotic therapy or immunoglobulin on iNfections in hAematoLogy Platform trial (RATIONAL-PT)\" w.w.w.anzctr.org.au: ANZCTR; 2024 [Available from: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=387826&isReview=true. Accessed October 28, 2015."},{"key":"10.1016\/j.tmrv.2025.150935_bib0009","unstructured":"McQuilten Zea. RATIONAL Platform trial - role of antibiotic therapy or immunoglobulin on iNfections in hAematoLogy - Platform trial (RATIONAL-PT) 2025 [Available from: https:\/\/www.rationaltrial.com\/about-rational-pt. Accessed October 28, 2015"},{"issue":"1","key":"10.1016\/j.tmrv.2025.150935_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1513750","article-title":"Adaptive randomization of Neratinib in early breast cancer","volume":"375","author":"Park","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tmrv.2025.150935_bib0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of Veliparib-carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tmrv.2025.150935_bib0012","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.tmrv.2025.150935_bib0013","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.tmrv.2025.150935_bib0014","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1093\/cid\/ciaa334","article-title":"Resist the temptation of response-adaptive randomization","volume":"71","author":"Proschan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2025.150935_bib0015","series-title":"I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY) - NCT01042379 - results overview [Internet]","year":"2009"},{"issue":"4","key":"10.1016\/j.tmrv.2025.150935_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tmrv.2025.150935_bib0017","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.tmrv.2025.150935_bib0018","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2020.7648","article-title":"Lessons from adaptive randomization: spying the I-SPY2 trial in breast cancer","volume":"18","author":"Gyawali","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150935_bib0019","first-page":"185","article-title":"Response-adaptive randomization in clinical trials: from myths to practical considerations","volume":"38","author":"Robertson","year":"2023","journal-title":"Stat Sci"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150935_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/pst.1845","article-title":"Response-adaptive designs for binary responses: how to offer patient benefit while being robust to time trends?","volume":"17","author":"Villar","year":"2018","journal-title":"Pharm Stat"},{"issue":"18","key":"10.1016\/j.tmrv.2025.150935_bib0021","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/jama.2023.21407","article-title":"Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials","volume":"330","author":"Adhikari","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.tmrv.2025.150935_bib0022","doi-asserted-by":"crossref","first-page":"m2670","DOI":"10.1136\/bmj.m2670","article-title":"Covid-19: the inside story of the RECOVERY trial","volume":"370","author":"Wise","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.tmrv.2025.150935_bib0023","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2025.150935_bib0024","unstructured":"RECOVERY Collaborative Group. RECOVERY trial results and publications oxford, UK: University of Oxford; [Available from: https:\/\/www.recoverytrial.net\/results."},{"issue":"8","key":"10.1016\/j.tmrv.2025.150935_bib0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.tmrv.2025.150935_bib0026","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with Heparin in noncritically ill patients with Covid-19","volume":"385","year":"2021","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.tmrv.2025.150935_bib0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with Heparin in critically ill patients with Covid-19","volume":"385","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.tmrv.2025.150935_bib0028","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-024-08273-9","article-title":"Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England","volume":"25","author":"Pessoa-Amorim","year":"2024","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.tmrv.2025.150935_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46502","article-title":"Implementation of recommendations on the use of corticosteroids in severe COVID-19","volume":"6","author":"Camirand-Lemyre","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1016\/j.tmrv.2025.150935_bib0030","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMc2102446","article-title":"Platform trials - beware the noncomparable control group","volume":"384","author":"Dodd","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tmrv.2025.150935_bib0031","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.7861\/fhj.2021-0083","article-title":"Making trials part of good clinical care: lessons from the RECOVERY trial","volume":"8","author":"Pessoa-Amorim","year":"2021","journal-title":"Future Healthc J"},{"key":"10.1016\/j.tmrv.2025.150935_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejim.2022.09.018","article-title":"The RECOVERY trial: an analysis and reflection two years on","volume":"105","author":"Duncan","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.tmrv.2025.150935_bib0033","unstructured":"Morris T, Dahly D, Hood K, Gates S. Statistical review of effect of Dexamethasone in Hospitalized patients with COVID-19 - preliminary report 2020. doi:10.5281\/zenodo.3928540."},{"key":"10.1016\/j.tmrv.2025.150935_bib0034","article-title":"platform trials assessing therapies for hospitalized COVID-19 patients: informed consent forms omitted a few important elements of information","volume":"13","author":"Dal-R\u00e9","year":"2023","journal-title":"J Glob Health"},{"key":"10.1016\/j.tmrv.2025.150935_bib0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","article-title":"The REMAP-CAP (Randomized embedded multifactorial adaptive platform for Community-acquired pneumonia) study. Rationale and design","volume":"17","author":"Angus","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tmrv.2025.150935_bib0036","unstructured":"REMAP-CAP Investigators Published online, REMAP-CAP Core Protocol Version 3 dated 10 July 2019. Website: Superseded Protocol Documents \u2014 REMAP-CAP Trial (Accessed August 26, 2025)."},{"key":"10.1016\/j.tmrv.2025.150935_bib0037","unstructured":"REMAP-CAP InvestigatorsPublished online, REMAP-CAP pandemic appendix to the core protocol version 2.0 dated 18 May 2020, Website: Superseded Protocol Documents \u2014 REMAP-CAP Trial (Accessed August 26, 2025)."},{"issue":"13","key":"10.1016\/j.tmrv.2025.150935_bib0038","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"Bradbury","year":"2022","journal-title":"Jama"},{"issue":"25","key":"10.1016\/j.tmrv.2025.150935_bib0039","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1056\/NEJMoa2309995","article-title":"Simvastatin in critically ill patients with Covid-19","volume":"389","author":"Hills","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2025.150935_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2023.03.031","article-title":"Pragmatic' or 'streamlined': which term best fits the REMAP-CAP trial","volume":"113","author":"Dal-R\u00e9","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.tmrv.2025.150935_bib0041","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1503\/cmaj.202397","article-title":"Integrating research into clinical practice: challenges and solutions for Canada","volume":"193","author":"Lamontagne","year":"2021","journal-title":"CMAJ"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796325000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796325000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:08:03Z","timestamp":1765195683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796325000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0887796325000604"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2025.150935","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Practical Review of Adaptive Platform Trials","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2025.150935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150935"}}